eNeuron has joined the long list of biotechs to leave London’s AIM stock market. The stem cell biotech is letting go of its listing after money troubles persuaded it to free itself from the costs and regulatory obligations of the exchange. Trading of ReNeuron shares on London’s AIM growth market has been on hold since February, when the failure to secure a revenue-generating deal or additional equity funding drove the biotech to request a suspension. ReNeuron appointed administrators in March. Source: Fierce Biotech 30/8/24